Skip to content

Evaluation of effect of Lactobacillus plantarum 22A-3 on improvement of skin and bowel conditions

Evaluation of effect of Lactobacillus plantarum 22A-3 on improvement of skin and bowel conditions - Evaluation of effect of Lactobacillus plantarum 22A-3 on improvement of skin and bowel conditions

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000025951
Enrollment
100
Registered
2017-03-06
Start date
2017-03-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Intake of test food (1 capsul/day, 4 weeks) Intake of placebo food (1 capsul/day, 4 weeks)

Sponsors

SOUKEN Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Japanese males and females aged 20-59 years 2)Subjects who are concerned about their dry skin 3)Subjects who are concerned about their rough skin 4)Subjects who are concerned about rough skin due to drying etc. to any of measurement region every year from October to March 5)Subjects who can abstain 6)Subjects whose written informed consent has been obtained 7)Subjects with 3-5 defections/week

Exclusion criteria

Exclusion criteria: 1)Subjects who are usually take functional foods which would affect this study 2)Subjects who may show skin allergies symptoms and with skin hypersensitivity 3)Subjects who are likely to have allergy symptoms depending on the test food 4)Subjects who have the skin symptom such as a wound, an eruption, a wart, a burn, art make around the corner of the eye 5)Subjects who regularly go to dermatology hospital 6)Subjects who pregnant or lactating 7)Subjects who participates in the other clinical study 8)Subjects who regularly use drug which affect this study 9)Subjects who use Mesaic, Eye tape, or Eylash extention 10)Subjects who judged as unsuitable for the study by the investigator 11)Subjects who have abnormality in the skin of the measurement region 12)Subjects who suffers pollen allergy and taking medicine 13)Subjects who have chronic skin symptoms such as atopic dermatitis

Design outcomes

Primary

MeasureTime frame
Evaluation of skin condition(Color difference, transepidermal water loss, skin hydration) and defection after intervention

Secondary

MeasureTime frame
questionnaires

Countries

Japan

Contacts

Public ContactKo Masuda

SOUKEN Co., Ltd. Management division

k_masuda@mail.souken-r.com03-5408-1555

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026